Chronic lymphocytic leukemia/small

Precursor B-cell neoplasm Precursor B-lymphoblastic leukemia/lymphoma Mature (peripheral) B-cell neoplasms B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma... 

B cell neoplasms based on morphology, immunophenotype, and genotype often, but not always, correspond to stages of B cell development. However, some B cell lymphomas either do not clearly correspond to a specific developmental stage (i.e., appear to be of variable origin such as chronic lymphocytic leukemia/small lymphocytic lymphoma) or do not appear to be related to any known stage of normal development (i.e., hairy cell leukemia) (H10). 

CLL/SLL, Chronic lymphocytic leukemia/small lymphocytic lymphoma MCL, mantle cell lymphoma FL, follicular lymphoma MZL/MALT, marginal zone lymphoma/mucosa-associated lymphoid tisuse lymphoma SMZL, splenic marginal zone lymphoma HCL, hairy cell leukemia DLCL, diffuse large-cell lymphoma PCM, plasma cell myeloma BCL-1, cyclin D1 FDC MW, Follicular dendritic cell meshworks CK, cytokeratin LELs, lymphoepitheilal lesions. 

K30. Kroft, S. H., Dawson, D. B., and McKenna, R. W., Large cell lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. A flow cytometric analysis of seven cases. Am. J. Clin. Pathol. 115, 385-395 (2001). 

B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA... 

Hairy cell leukemia chronic lymphocytic leukemia small cell non-Hodgkin s lymphoma... 

Shao H, Xi L, Raffeld M, Feldman AL, Kettoling RP, Knudson R, Rodriguez-Canales J, Hanson J, Pittaluga S, Jaffe ES. Clonally related histiocytic/dendtitic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma a study of seven cases. Mod Pathol. 2011 24 1421-32. 

Hainsworth, J.D., Litchy, S., Barton, J.H., Houston, G.A., Hermann, R.C., Bradof, J.E., and Greco, RA., Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma a phase II trial of the Minnie Pearl Gancer Research Network, /. Clin. Oncol., 21,1746-2751, 2003. 

NK cells, monocytes, macrophages, and a small population of granulocytes. Currently, alemtuzumab is approved for the treatment of -cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and have failed fludarabine therapy. Alemtuzumab appears to deplete leukemic and normal cells by direct antibody-dependent lysis. Patients receiving this antibody become lymphopenic and may also become neutropenic, anemic, and thrombocytopenic. As a result patients should be closely monitored for opportunistic infections and hematologic toxicity. 

D26. Dunphy, C. H., Wheaton, S. E., and Perkins, S. L., CD23 expression in transformed small lymphocytic lymphomas/chronic lymphocytic leukemias and blastic tranformations of mantle cell lymphoma. Mod. Pathol. 10, 818-822 (1997). 

K8. Kilo, M. N., and Dorfman, D. M., The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am. J. Clin. Pathol. 105, 451—457 (1996). 

Another small-molecule pan-Bcl-2 inhibitor that mimicks BH3-only proteins, GX15-070 (developed by GeminX, Montreal, Canada) (Fig. 3k), was shown to be a potent apoptosis inducer in breast cancer, chronic lymphocytic leukemia, multiple myeloma, and mantle cell lymphoma cell lines (76-79). 

Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma implications for clinical trials in this patient population. Cancer 2002 94(7) 2033-9. 

Brain tumors Carcinoid tumors Chronic lymphocytic leukemia Colorectal cancer Esophageal cancer Head and neck cancers Kaposi s sarcoma Metastatic melanoma Mycosis fungoides Non-small-cell lung cancer Ovarian cancer ... 

ANLL, acute nonleukocytic leukemia ALL, acute lymphocytic leukemia BM, bone marrow CIcr, creatinine clearance CLL, chronic lymphocytic leukemia CML, chronic myelogenous leukemia DNA, deoxyribonucleic acid HD, Hodgkin s disease HSV, herpes simplex virus IT, intrathecal MDS, myelodysplastic syndrome NHL, non-Hodgkin s lymphoma NSCLC, non-small-cell lung cancer PCP, Pneumocystis carinii pneumonia RNA, ribonucleic acid WBC, white blood cells. 

CD25 functions as a low-affinity interleukin-2 receptor and may be found on a number of cell types including activated T cells. This antigen is characteristically expressed on hairy cell leukemia, mast cell lesions, and certain T-cell malignancies but may be seen at low levels in certain B-cell lymphomas, particularly small cell lymphocytic lymphoma/chronic lymphocytic leukemia. Targeted therapy is available for this antigen (Ontak). 

INTERPHASE FISH Several recurrent genetic abnormalities identified in small cell lymphocytic lymphoma/chronic lymphocytic leukemia have had a direct relationship to disease progression. These abnormalities are ... 

Huang JC, Finn WG, Goolsby CL, et al. CD5- small B-cell leukemias are rarely classifiable as chronic lymphocytic leukemia. Am J Clin Pathol. 1999 111(1) 123-130. 

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)... 

ABBREVIATIONS CLL, chronic lymphocytic leukemia EGFR, epidermal growth factor receptor NSCLC, non-small cell lung cancer VEGF, vascular endothelial growth factor. 

NHL non-Hodgkin s lymphoma CLL chronic lymphocytic leukemia AML acute myelogenous leukemia CRC colorectal cancer NSCLC non-small cell lung cancer EGFR epidermal growth factor receptor VEGF vascular endothehal growth factor. 

Forre et aL (1976) have developed subgroup-specific antisera to human myeloma heavy chains. The antisera were developed from heavy chains whose variable region amino acid sequences were known, thus providing a primary structural basis for the serology. A survey of 167 nonsequenced myeloma proteins showed a ratio of 1 2 3 for VhI VhII VhIII. This same group (Forre et aL, 1977) has detected Vh determinants on the surface of lymphocytes from patients with chronic lymphocytic leukemia. The number of patients studied is too small to allow conclusions to be drawn about distribution of Vh subgroups on the cell surface. 

Pharmacyclics acquired Celera s small molecule Btk inhibitor program in April 2006 subsequently, PCI-32765 (ibrutinib) was chosen for further preclinical and clinical developments. Ibrutinib (trade name Imbruvica), currently jointly developed and marketed by Pharmacyclics and Janssen Biotech, Inc. (a subsidiary of Johnson Johnson), was approved on November 13, 2013 by the US Food and Drug Administration (FDA) for the treatment of mantle cell lymphoma (MCL), and thus became the first approved drug that directly targets Btk. On February 12, 2014, the FDA has expanded the approval of ibrutinib to include the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy, and further expansion to patients with 17p deletion in CLL was approved on July 28, 2014. 

---